Clinical Trial Update: Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating gabapentin to reduce the need for strong opioid use in head and neck cancer patients has been withdrawn. The study was sponsored by Uni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Neuropathic Pain
• Radiation-induced Neuropathy

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Head Neck Cancer, Radiation Neuropathy | Phase 3 | Status: WITHDRAWN